Holly F. Lofton MD DABOM
Obesity Medicine & Nutrition
Clinical Associate Professor, Medicine and Surgery, New York University School of Medicine, Director, Medical Weight Management Program
Join to View Full Profile
530 1st AvenueSuite 10SNew York, NY 10016
Dr. Lofton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Geisinger Health SystemFellowship, Obesity Medicine and Nutrition Support, 2007 - 2008
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 2005 - 2007
Medical College of GeorgiaInternship, Internal Medicine, 2004 - 2005- Medical College of Georgia at Augusta UniversityClass of 2004
Certifications & Licensure
FL State Medical License 2020 - Present
NY State Medical License 2010 - 2026
NJ State Medical License 2024 - 2025
PA State Medical License 2007 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Obesity Medicine Obesity Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery Start of enrollment: 2017 May 22
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Start of enrollment: 2022 Oct 11
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Start of enrollment: 2019 Dec 04
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsGLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study.Babak J Orandi, Yusi Chen, Yiting Li, Garyn T Metoyer, Krista L Lentine
The Lancet. Diabetes & Endocrinology. 2025-03-04 - Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes.Gregory J Grosicki, J Graham Thomas, Nikhil V Dhurandhar, Holly Lofton, Steven B Heymsfield
Diabetes, Obesity & Metabolism. 2025-03-01 - A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.Holly F Lofton, Gabrielle Maranga, Robert Hold, George Fielding, Heekoung Youn
Surgery for Obesity and Related Diseases. 2025-02-01
Press Mentions
The Skinny on Microdosing GLP-1 DrugsMarch 6th, 2025- Focus: Doctors Struggle to Get Wegovy for Older Americans with Heart DiseaseAugust 15th, 2024
- Ozempic Could Be an Accidental Treatment for AddictionMay 24th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
